Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Hypertension, Left Ventricular Hypertrophy
About this trial
This is an interventional basic science trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
History of hypertension
- Seated systolic BP < 160 mmHg and diastolic < 100 mmHg if on antihypertensives
- Seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives
LVH by echocardiogram
- For men: LV mass index > 134 g/m2
- For women: LV mass index > 110 g/m2
- We will also allow inclusion of people with pre-diabetes and treated hypothyroidism
Exclusion Criteria:
- Use of MR antagonist (eplerenone, spironolactone, or finerenone) or amiloride (amiloride inhibits ENaC, which is a key mediator of MR's actions) within the past year
- Orthostatic hypotension
- Major medical illness, including diabetes mellitus
- Documented coronary disease (prior revascularization and/or myocardial infarction
- LV ejection fraction < 40%
- Cerebrovascular disease
- Peripheral vascular disease
- Known genetic cardiomyopathy
- Renal disease (eGFR < 60 mL/min/1.73m2)
- Hepatic disease
- Bronchospastic lung disease
- Alcohol or substance abuse
- Hormone replacement therapy
- Abnormal values for electrolytes, liver enzymes or TSH
- Hemoglobin A1c ≥ 6.5%
- Pregnancy or lactation
- All individuals <18 and >70 years will be excluded due to safety concerns of administering an angiotensin-II infusion in these patient groups.
Sites / Locations
- Brigham and Women's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Eplerenone
Chlorthalidone + potassium
Participants be placed on enalapril 10 mg and weaned off their other anti-hypertensives prior to the Pre-Treatment Assessment. Amlodipine (5 to 10 mg) will be added if needed to control blood pressure. After the Pre-Treatment Assessment, participants randomized to this arm will receive 50 mg eplerenone . At 2 weeks, eplerenone will be increased to 100 mg. Amlodipine (5 to 10 mg) will be added at 6 weeks or later if needed to achieve the BP target of <135/85 mmHg.
Participants be placed on enalapril 10 mg and weaned off their other anti-hypertensives prior to the Pre-Treatment Assessment. Amlodipine (5 to 10 mg) will be added if needed to control blood pressure. After the Pre-Treatment Assessment, participants randomized to this arm will receive 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium. Amlodipine (5 to 10 mg) will be added at 6 weeks or later if needed to achieve the BP target of <135/85 mmHg.